The effect of sunitinib on biomarkers and tumor heterogeneity in metastatic clear cell renal cancer. Open-label, phase II raptor study of everolimus (EVE) for papillary mRCC: Efficacy in type 1 and ...

Effect of zoledronic acid (ZA) versus placebo on bone mineral density (BMD) in androgen-deprived prostate cancer patients with and without bone metastases (mets) This is an ASCO Meeting Abstract from ...

There is great interest in evaluating the link between hypercalcemia and prognosis in ccRCC by researching the genes that influence calcium levels. RCC histology was associated with survival after ...

First described in 1985, chromophobe RCC accounts for approximately 5% of renal tumors.15 This RCC subtype has a better prognosis than either clear cell or papillary RCC, but it is worth noting that ...